HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Neuromuscular therapeutics by RNA-targeted suppression of ACHE gene expression.

Abstract
RNA-targeted therapeutics offers inherent advantages over small molecule drugs wherever one out of several splice variant enzymes should be inhibited. Here, we report the use of Monarsen, a 20-mer acetylcholinesterase-targeted antisense agent with three 3'-2'o-methyl-protected nucleotides, for selectively attenuating the stress-induced accumulation of the normally rare, soluble "readthrough" acetylcholinesterase variant AChE-R. Acetylcholine hydrolysis by AChE-R may cause muscle fatigue and moreover, limit the cholinergic anti-inflammatory blockade, yielding inflammation-associated pathology. Specific AChE-R targeting by Monarsen was achieved in cultured cells, experimental animals, and patient volunteers. In rats with experimental autoimmune myasthenia gravis, oral delivery of Monarsen improved muscle action potential in a lower dose regimen (nanomolar versus micromolar), rapid and prolonged manner (up to 72 h versus 2-4 h) as compared with the currently used small molecule anticholinesterases. In central nervous system neurons of both rats and cynomolgus monkeys, systematic Monarsen treatment further suppressed the levels of the proinflammatory cytokines interleukin-1 (IL-1) and IL-6. Toxicology testing and ongoing clinical trials support the notion that Monarsen treatment would offer considerable advantages over conventional cholinesterase inhibitors with respect to dosing, specificity, side effects profile, and duration of efficacy, while raising some open questions regarding its detailed mechanism of action.
AuthorsAmir Dori, Hermona Soreq
JournalAnnals of the New York Academy of Sciences (Ann N Y Acad Sci) Vol. 1082 Pg. 77-90 (Oct 2006) ISSN: 0077-8923 [Print] United States
PMID17145929 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Cholinesterase Inhibitors
  • Interleukin-1
  • Interleukin-6
  • Neuromuscular Agents
  • Oligoribonucleotides, Antisense
  • Acetylcholinesterase
  • Acetylcholine
Topics
  • Acetylcholine (biosynthesis, genetics)
  • Acetylcholinesterase (drug effects)
  • Animals
  • Cholinesterase Inhibitors (pharmacology, therapeutic use)
  • Gene Expression (drug effects)
  • Interleukin-1 (blood)
  • Interleukin-6 (blood)
  • Macaca fascicularis
  • Myasthenia Gravis, Autoimmune, Experimental (drug therapy)
  • Neuromuscular Agents (pharmacology, therapeutic use)
  • Neuromuscular Diseases (drug therapy)
  • Oligoribonucleotides, Antisense (administration & dosage, pharmacology, therapeutic use)
  • Rats

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: